01
Cash & equivalents increased 95.5%
Cash & equivalents changed +95.5% from the comparable as-filed period.
$6.7M→$13.1MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTGain Therapeutics, Inc.'s latest supported as-filed period reports revenue of $55,180. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +95.5% from the comparable as-filed period.
Debt changed -23.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net income changed +19.5% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
GANX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-094048SEC ↗8-KAug 11, 2026Period Aug 11, 20260001104659-26-094041SEC ↗4Jul 17, 2026Period Jul 15, 20260001104659-26-084439SEC ↗4Jul 17, 2026Period Jul 15, 20260001104659-26-084438SEC ↗4Jul 17, 2026Period Jul 15, 20260001104659-26-084437SEC ↗4Jul 17, 2026Period Jul 15, 20260001104659-26-084435SEC ↗4Jul 17, 2026Period Jul 15, 20260001104659-26-084434SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 15, 2026Filed Jul 17, 2026 | GOLDSTEIN DOV A MDDirector | Grant Or AwardDirect | 25,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed +8.0% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Research & development changed -22.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Stock-based compensation changed +8.4% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001104659-26-084433